GLP-1 Drugs Deliver Different Benefits Beyond Weight Loss
A large BMJ analysis finds tirzepatide and CagriSema lead on weight reduction, while semaglutide currently has the strongest evidence for certain cardiovascular outcomes
A review of 262 randomized trials involving nearly 100,000 adults found that obesity medications vary substantially in weight loss, adverse effects, cardiovascular outcomes, and treatment discontinuation.
Tirzepatide and CagriSema produced the largest estimated weight reductions at one year, but injectable semaglutide had the clearest evidence for reducing myocardial infarction and all-cause mortality.
The results support individualized obesity treatment rather than declaring a single medication the universal winner.
The Most Effective Drug Depends on the Goal
The expanding obesity drug market is often presented as a race to determine which medication produces the greatest percentage of weight loss. That comparison is useful, but it is incomplete.
A person seeking maximum weight reduction may make a different choice from someone with established cardiovascular disease, heart failure, difficulty tolerating gastrointestinal symptoms, concern about muscle loss, or limited ability to remain on long-term treatment.
The new BMJ analysis helps move obesity medicine away from a single leaderboard and toward a multidimensional treatment decision. Weight loss remains important, but it is only one outcome among several that matter to patients.
Study Details
Researchers conducted a systematic review and network meta-analysis comparing medications used in adults with overweight or obesity. The study included traditional obesity drugs, GLP-1 receptor agonists, dual and triple incretin therapies, and several investigational agents.
The investigators searched Medline, Embase, and the Cochrane Library through November 12, 2025. They included randomized controlled trials lasting at least 12 weeks that compared a medication with lifestyle intervention, placebo, or another drug.
The final analysis included 262 trials and 99,791 participants. The median participant age was 49 years, approximately 63% were women, and the median body mass index was 34.7. Follow-up lasted a median of only 26 weeks, an important limitation when considering long-term cardiovascular, kidney, functional, and quality-of-life outcomes.
Methodology
A network meta-analysis allows researchers to estimate how multiple treatments compare, even when many of the drugs have not been tested directly against each other in head-to-head trials.
For example, when drug A and drug B have each been compared with placebo in separate studies, statistical modeling can provide an indirect estimate of how A might compare with B. This approach is valuable when the treatment field is growing faster than direct comparative trials can be completed.
However, an indirect comparison is not equivalent to randomizing patients directly between the two medications. Differences in study populations, doses, trial duration, adherence, and outcome definitions can influence the estimates.
The researchers examined 24 patient-important outcomes and evaluated the certainty of the evidence using the GRADE framework. They also assessed study bias using the Cochrane Risk of Bias 2 tool.
Key Findings
Tirzepatide produced the largest estimated weight reduction. At one year, tirzepatide was associated with an average 14.9% greater reduction in body weight than lifestyle modification alone.
CagriSema produced a similar estimated reduction. The investigational combination of cagrilintide and semaglutide was associated with 14.8% greater weight loss, although the confidence interval was wider.
Oral semaglutide and orforglipron also produced substantial weight loss. Estimated reductions were 10.9% for oral semaglutide and 9.9% for orforglipron.
Injectable semaglutide produced approximately 9.8% greater weight loss. Its estimated weight reduction was lower than tirzepatide in the analysis, but its evidence base included important cardiovascular outcome data.
Semaglutide and tirzepatide were associated with lower heart failure risk. Injectable semaglutide had a risk ratio of 0.43, while tirzepatide had a risk ratio of 0.49.
Injectable semaglutide had the clearest mortality and heart attack evidence. It was associated with a 19% relative reduction in all-cause mortality and a 28% relative reduction in myocardial infarction.
Greater weight loss often came with greater treatment burden. Gastrointestinal adverse events were more frequent with oral semaglutide, orforglipron, tirzepatide, and some non-GLP-1 treatments.
Fatigue was an important adverse effect for some medications. Increased fatigue was identified with naltrexone-bupropion, orforglipron, and CagriSema.
Tirzepatide reduced both fat and lean mass. It was associated with the largest reduction in fat mass at 25.7%, but also an 8.3% reduction in lean mass.
Evidence for newer drugs remains less mature. The certainty of evidence for agents such as retatrutide, mazdutide, and ecnoglutide was rated low or very low because fewer completed trials and less long-term evidence were available.
Quality of Life Is Still an Open Question
The study’s conclusion that most obesity drugs did not produce a meaningful improvement in quality of life deserves careful interpretation.
The quality-of-life analysis included 43 trials and more than 45,000 participants. Researchers used a 10-point improvement on the SF-36 survey as the threshold for a clinically meaningful benefit.
That cutoff is a judgment-based standard, not an absolute biological boundary. A smaller measured change may still be meaningful to someone who can walk farther, sleep better, experience less joint pain, reduce food preoccupation, or participate more fully in daily activities.
Experts commenting through the UK Science Media Centre cautioned that the findings should not be interpreted as proof that patients receive no day-to-day benefit. They noted that different quality-of-life thresholds could produce different conclusions and that many trials were not designed primarily to measure long-term functional improvement.
The more defensible conclusion is that current trials have not consistently demonstrated a large improvement using this particular threshold and measurement tool.
Cardiovascular Benefits Cannot Be Generalized Across Every GLP-1 Drug
The cardiovascular findings also require precision.
Injectable semaglutide was associated with reductions in myocardial infarction and all-cause mortality, while semaglutide and tirzepatide were associated with lower heart failure risk. These findings are clinically important, but they do not establish a cardiovascular benefit for every drug grouped under the broad GLP-1 or incretin label.
Some agents have dedicated cardiovascular outcome trials. Others have mainly been studied in shorter weight-loss trials that were neither long enough nor large enough to detect differences in heart attacks, kidney failure, or mortality.
Absence of demonstrated benefit is therefore not always evidence of no benefit. For newer agents, it may simply mean the necessary outcome trials have not yet been completed.
What the Results Mean for Patients
Patients should not interpret the rankings as a reason to change medications solely because another drug produced greater average weight loss in a statistical comparison.
The most appropriate treatment depends on several questions:
How much weight reduction is clinically necessary? Is cardiovascular disease already present? Is heart failure a major concern? Has the patient previously experienced severe nausea, vomiting, constipation, diarrhea, or fatigue? Is maintaining muscle mass a priority? Can the medication be obtained and continued at an affordable cost?
A medication that produces somewhat less average weight loss but remains tolerable and accessible may provide more long-term benefit than a more potent drug that is discontinued after several months.
Patients should also understand that obesity is commonly a chronic condition. Earlier evidence has shown that weight regain frequently follows the discontinuation of weight-management medications, so the sustainability of therapy should be considered before treatment begins.
Implications for Healthcare Providers
The study strengthens the case for shared decision-making built around patient priorities rather than a universal prescribing hierarchy.
For a patient primarily seeking maximum weight reduction, tirzepatide may be especially compelling based on the current evidence. For a patient with established cardiovascular disease, injectable semaglutide may have a stronger outcomes-based argument because of its demonstrated association with reduced myocardial infarction and mortality.
For patients at risk of frailty or sarcopenia, clinicians should assess strength, physical function, protein intake, and resistance exercise rather than monitoring body weight alone. Lean-mass loss does not automatically equal pathological muscle loss, but it should not be treated as clinically irrelevant, particularly in older adults.
Gastrointestinal tolerance, fatigue, route of administration, dosing frequency, medication access, insurance coverage, and the probability of long-term adherence should also be incorporated into the initial treatment decision.
The accompanying BMJ editorial described the analysis as a step toward individualized obesity care while emphasizing that aggregated trial data cannot fully account for the characteristics that determine how a particular patient will respond.
The Missing Evidence
The analysis is broad, but it cannot answer every clinically important question.
Many included trials were relatively short. The study also lacked individual participant data, limiting the researchers’ ability to determine whether age, sex, baseline body composition, cardiovascular risk, diabetes status, prior treatment, or other characteristics modified the relative effectiveness of each drug.
Network comparisons also rely heavily on indirect evidence. They are useful for informing decisions, but they should not replace well-designed head-to-head trials.
Future studies should compare the leading medications directly and measure outcomes beyond body weight, including strength, physical functioning, cardiovascular events, kidney outcomes, treatment persistence, patient-reported well-being, and outcomes after therapy is stopped.
The Bottom Line
The study does not identify one obesity medication that is best for every patient.
Tirzepatide and CagriSema currently lead the weight-loss estimates. Injectable semaglutide has the strongest evidence in this analysis for reducing myocardial infarction and all-cause mortality. Several agents produce substantial gastrointestinal side effects, some increase fatigue, and the long-term evidence for many next-generation drugs remains limited.
The next stage of obesity medicine will not be defined only by increasingly powerful weight-loss drugs. It will be defined by selecting the right treatment for the right patient, preserving health and function during weight loss, and generating better evidence about the outcomes patients value most.